JP2005532364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532364A5 JP2005532364A5 JP2004512754A JP2004512754A JP2005532364A5 JP 2005532364 A5 JP2005532364 A5 JP 2005532364A5 JP 2004512754 A JP2004512754 A JP 2004512754A JP 2004512754 A JP2004512754 A JP 2004512754A JP 2005532364 A5 JP2005532364 A5 JP 2005532364A5
- Authority
- JP
- Japan
- Prior art keywords
- gatifloxacin
- degrees
- crystalline form
- solution
- exposure time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 29
- 229960003923 gatifloxacin Drugs 0.000 claims description 18
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- 238000010586 diagram Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- RMJMZKDEVNTXHE-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCNC(C)C1 RMJMZKDEVNTXHE-UHFFFAOYSA-N 0.000 claims description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 238000001816 cooling Methods 0.000 claims 5
- 239000002002 slurry Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38909302P | 2002-06-14 | 2002-06-14 | |
| US42333802P | 2002-11-01 | 2002-11-01 | |
| PCT/US2003/019046 WO2003105851A1 (en) | 2002-06-01 | 2003-06-16 | Novel crystalline forms of gatifloxacin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532364A JP2005532364A (ja) | 2005-10-27 |
| JP2005532364A5 true JP2005532364A5 (enExample) | 2006-05-11 |
Family
ID=29740100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004512754A Pending JP2005532364A (ja) | 2002-06-14 | 2003-06-16 | ガチフロキサシンの新規結晶質形態 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7411067B2 (enExample) |
| EP (1) | EP1471911A1 (enExample) |
| JP (1) | JP2005532364A (enExample) |
| CN (1) | CN1674902A (enExample) |
| AU (1) | AU2003243615A1 (enExample) |
| CA (1) | CA2489377A1 (enExample) |
| IL (1) | IL165690A0 (enExample) |
| WO (1) | WO2003105851A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118546A1 (en) * | 2004-06-04 | 2005-12-15 | Matrix Laboratories Ltd | Novel crystalline forms of gatifloxacin |
| CA2621616A1 (en) * | 2007-02-19 | 2008-08-19 | Alcon Research, Ltd. | Topical gatifloxacin formulations |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0629621B1 (en) | 1992-01-31 | 2001-10-24 | Chugai Seiyaku Kabushiki Kaisha | Crystal of quinolonecarboxylic acid derivative hydrate |
| JP3449658B2 (ja) | 1994-12-21 | 2003-09-22 | 杏林製薬株式会社 | 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
| US6413969B1 (en) | 2000-09-13 | 2002-07-02 | Bristol-Myers Squibb Company | Gatifloxacin pentahydrate |
| CA2481308A1 (en) | 2002-04-08 | 2003-10-23 | Dr. Reddy's Laboratories Limited | Anhydrous crystalline forms i and ii of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) |
-
2003
- 2003-06-16 AU AU2003243615A patent/AU2003243615A1/en not_active Abandoned
- 2003-06-16 US US10/462,945 patent/US7411067B2/en not_active Expired - Fee Related
- 2003-06-16 CN CNA038193094A patent/CN1674902A/zh active Pending
- 2003-06-16 EP EP03760424A patent/EP1471911A1/en not_active Withdrawn
- 2003-06-16 CA CA002489377A patent/CA2489377A1/en not_active Abandoned
- 2003-06-16 JP JP2004512754A patent/JP2005532364A/ja active Pending
- 2003-06-16 WO PCT/US2003/019046 patent/WO2003105851A1/en not_active Ceased
-
2004
- 2004-12-09 IL IL16569004A patent/IL165690A0/xx unknown
-
2008
- 2008-07-01 US US12/217,251 patent/US20080269488A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI406661B (zh) | ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基〕-３-（４-吡啶-３-基-嘧啶-２基胺基）-苯甲醯胺之結晶型 | |
| CA2194984C (en) | 4-indole derivatives as serotonin agonists and antagonists | |
| JP5411734B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| JP4931874B2 (ja) | リモナバントの結晶多形の製造方法 | |
| JP2020125307A (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
| NO171453B (no) | Fremgangsmaate for fremstilling av krystallinsk paroxetin-hydroklorid-hemihydrat | |
| JP5656834B2 (ja) | 肥満細胞トリプターゼインヒビターとしての［４−（５−アミノメチル−２−フルオロ−フェニル）−ピペリジン−１−イル］−［７−フルオロ−１−（２−メトキシ−エチル）−４−トリフルオロメトキシ−１ｈ−インドール−３−イル］−メタノン | |
| TWI455934B (zh) | ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基-３-（４-吡啶-３-基-嘧啶-２-基胺基）-苯甲醯胺之鹽 | |
| CZ342896A3 (en) | Crystalline hydrochloride of (r)-(-)-2-{n-£4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-1-yl)-butyl|- -aminomethyl}-chroman, process of its preparation, pharmaceutical composition containing thereof and its use | |
| JP2001519812A (ja) | ソマトスタチン作動薬 | |
| JP2006514110A (ja) | Ｉｐ受容体アンタゴニストとしてのフェニルまたはヘテロアリールアミノアルカン誘導体 | |
| IE922523A1 (en) | New 5-isoquinolinesulfonamides process for preparing them and pharmaceutical compositions containing them | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| JP2004527516A (ja) | ピペラジン誘導体、それらの製造方法および治療における使用（５ｈｔ１ｂ受容体活性） | |
| CA2409258A1 (en) | Novel amorphous form of omeprazole salts | |
| TW200922585A (en) | Amino 1,2,4-triazole derivatives as modulators of mGluR5 | |
| CN101137638A (zh) | 取代的氨基烷基-与酰氨基烷基-苯并吡喃衍生物 | |
| CA2193388C (en) | Aryl and heteroaryl alkoxynaphthalene derivatives | |
| KR102604227B1 (ko) | 리피테그라스트 결정형 및 이를 포함하는 약제학적 조성물 | |
| HU184785B (en) | Process for producing new indole derivatives | |
| FI85138C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-fenylpropylindolderivat. | |
| JP2009517431A (ja) | Ｈ３調節剤として使用するための１，１−ジオキソ−チオモルホリニルインドリルメタノン誘導体 | |
| AU2010284832A1 (en) | A process for the synthesis of naratriptan | |
| JP4664275B2 (ja) | ベンゾフラン誘導体ならびに抗うつ剤および抗不安剤としてのそれらの使用 | |
| JP2005539035A (ja) | ２−チオ置換イミダゾール誘導体および製薬におけるその使用 |